Welcome to our dedicated page for Xenon Pharmaceut news (Ticker: XENE), a resource for investors and traders seeking the latest updates and insights on Xenon Pharmaceut stock.
Xenon Pharmaceuticals Inc. (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company whose news flow centers on clinical progress, scientific data, and corporate developments in neurology and psychiatry. The company is advancing azetukalner, a novel, potent, selective Kv7 potassium channel opener in Phase 3 clinical trials for epilepsy, major depressive disorder (MDD), and bipolar depression (BPD), alongside early-stage Kv7 and NaV1.7 programs in pain and a NaV1.1 program in Dravet syndrome.
News related to XENE often covers clinical milestones, such as enrollment updates and anticipated topline data from Phase 3 studies like X-TOLE2 and X-TOLE3 in focal onset seizures (FOS), X-ACKT in primary generalized tonic-clonic seizures (PGTCS), and the X-NOVA and X-CEED programs in MDD and BPD. Xenon also issues press releases on long-term X-TOLE open-label extension (OLE) data, which include multi-year seizure frequency reductions and analyses of seizure freedom patterns with extended azetukalner treatment.
Investors and clinicians following XENE can expect scientific conference coverage from meetings such as the American Epilepsy Society Annual Meeting, where Xenon presents posters on epilepsy outcomes, depression burden in epilepsy, and pre-clinical data from its NaV1.1 Dravet syndrome program. Additional news items include corporate updates like quarterly financial results, investor conference presentations, investor webinars, and executive appointments, such as the appointment of a Chief Financial Officer in connection with anticipated commercialization activities.
Bookmark this page to monitor Xenon’s latest announcements on its Phase 3 epilepsy and mood disorder programs, early-stage pain pipeline, partnered work with Neurocrine Biosciences, and ongoing regulatory and investor communications.
Xenon Pharmaceuticals (Nasdaq: XENE) announced inducement equity grants to seven new non-officer employees comprising an aggregate of 25,600 share options and 15,000 restricted share units (RSUs), effective April 30, 2026, approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4).
The share options carry a $56.04 exercise price, vest over four years, have a 10-year term, and RSUs vest 25% annually over four years, all subject to the company’s inducement equity incentive plan and continued service requirements.
Xenon Pharmaceuticals (Nasdaq: XENE) will report Q1 2026 financial results and provide a business update after U.S. markets close on May 7, 2026 at 4:30pm ET.
A live webcast will be available via the company website; dial-in details and conference ID 7898598 are provided for callers. Xenon’s lead molecule, azetukalner, is in Phase 3 for epilepsy, major depressive disorder, and bipolar depression. The company also has Phase 1 KV7 and NaV1.7 programs targeting pain and maintains offices in Vancouver and Boston.
Xenon (NASDAQ: XENE) presented Phase 3 X-TOLE2 and 48-month X-TOLE OLE data for azetukalner in focal onset seizures at AAN 2026. In X-TOLE2, azetukalner 25 mg produced a -53.2% median percent change in monthly seizures versus -10.4% for placebo (p<0.0001).
In the ≥48-month OLE, month 48 MPC reached -90.9% and 38.2% of participants achieved ≥12 months seizure freedom; Xenon expects to submit an FDA NDA in Q3 2026.
Xenon Pharmaceuticals (Nasdaq: XENE) will present at four investor conferences in Q2 2026: Bloom Burton (Apr 22), Bank of America (May 14), RBC (May 19) and Jeffries (Jun 4).
Webcast details and replay availability will be posted on the company Investors section; dates and times are subject to change.
Xenon (Nasdaq: XENE) will present five abstracts at the AAN Annual Meeting April 18-22, 2026, including a Late-breaking Science oral and poster of topline Phase 3 X-TOLE2 results for azetukalner in focal onset seizures and a ≥48-month interim analysis from the X-TOLE open-label extension.
Additional presentations cover real-world titration burden, comorbidity impacts, and preclinical NaV1.1 Dravet data; Xenon will staff Booth #2330 in the exhibit hall.
Xenon Pharmaceuticals (Nasdaq: XENE) closed an upsized underwritten public offering on March 12, 2026, raising approximately $747.5 million in gross proceeds.
The company sold 12,236,843 common shares (including 1,710,526 shares from full exercise of the underwriters' option) and issued pre-funded warrants to purchase up to 877,194 common shares at $56.9999 each; each pre-funded warrant has an exercise price of $0.0001.
Xenon Pharmaceuticals (Nasdaq: XENE) priced an upsized underwritten public offering totaling 10,526,317 common shares and pre-funded warrants for 877,194 shares at $57.00 per common share (pre-funded warrants $56.9999), raising approximately $650.0 million in gross proceeds.
The offering includes a 30-day underwriter option to buy up to 1,710,526 additional common shares and is expected to close on or about March 12, 2026. The securities were registered on a shelf registration filed August 9, 2024. No sales are being made in Canada.
Xenon Pharmaceuticals (Nasdaq: XENE) announced a proposed underwritten public offering of $500.0 million of common shares, with underwriters having a 30-day option to purchase up to an additional $75.0 million. All shares are being offered by Xenon and the offering is subject to market and other conditions.
Joint book-running managers include J.P. Morgan, Jefferies, TD Cowen, Stifel, RBC Capital Markets, and William Blair; an effective shelf registration was filed on August 9, 2024. The offering will be made only by prospectus and prospectus supplement.
Xenon (Nasdaq: XENE) reported positive topline Phase 3 X-TOLE2 results for azetukalner in focal onset seizures (FOS) on March 9, 2026. The trial met its primary endpoint with a -53.2% median percent change (MPC) in monthly FOS frequency for 25 mg versus -10.4% for placebo (placebo-adjusted -42.7%, p=6e-12).
Key secondary RR50 was 54.8% (25 mg) versus 20.8% placebo. Safety was consistent with prior studies. Xenon plans to file an NDA in Q3 2026 and will present X-TOLE2 as a Late Breaking Science oral at AAN on April 19, 2026.
Xenon Pharmaceuticals (Nasdaq: XENE) will announce topline results from the Phase 3 X-TOLE2 study of azetukalner in focal onset seizures on Monday, March 9, 2026. A live webcast and replay will be available via the company's Investors website; conference call details are provided.
Conference call: 8:00 am ET (5:00 am PT) on March 9, 2026; dial-in and webcast registration information available.